MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma

Wiesner, Philipp; Tafelmeier, Maria; Chittka, Dominik; Choi, Soo–Ho; Zhang, Li; Byun, Young Sup; Almazan, Felicidad; Yang, Xiaohong; Iqbal, Navaid; Chowdhury, P.; Maisel, Alan; Witztum, Joseph L.; Handel, Tracy M.; Tsimikas, Sotirios; Miller, Yury I.

doi:10.1194/jlr.m036343

Cited by 78 publications

(49 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Findings that CCL2 can bind to oxidized LDL and thereby be carried by lipoprotein(a) in human plasma 78 may provide an additional mechanism of a tissueor site-specific localization and presentation of chemokines, not yet examined in atherosclerosis. Conversely, chemokine receptors have been found to directly regulate lipid levels and hyperlipidemia-induced inflammation, for example, modulating very-low-density lipoprotein receptor uptake.…”

Section: Discussionmentioning

confidence: 99%

Chemokines in Atherosclerosis

Zernecke

Weber

2014

ATVB

165

144

View full text Add to dashboard Cite

Chemokines play important roles in atherosclerotic vascular disease. Expressed by not only cells of the vessel wall but also emigrated leukocytes, chemokines were initially discovered to direct leukocytes to sites of inflammation. However, chemokines can also exert multiple functions beyond cell recruitment. Here, we discuss novel and recently emerging aspects of chemokines and their involvement in atherosclerosis. While reviewing newly identified roles of chemokines and their receptors in monocyte and neutrophil recruitment during atherogenesis and atheroregression, we also revisit homeostatic functions of chemokines, including their roles in cell homeostasis and foam cell formation. The functional diversity of chemokines in atherosclerosis warrants a clear-cut mechanistic dissection and stage-specific assessment to better appreciate the full scope of their actions in vascular inflammation and to identify pathways that harbor the potential for a therapeutic targeting of chemokines in atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemokines in Atherosclerosis

Zernecke

Weber

2014

ATVB

165

144

View full text Add to dashboard Cite

show abstract

“…Macrophage-derived foam cells accumulate in atheromatous plaques and lead to inflammation by secreting cytokines e.g., IL-6 and TNF-α (28). MCP-1 and IL-8, chemokines abundantly expressed in atherosclerotic lesions, attract monocytes into the plaque and potentially contribute to inflammation enhancement and atherosclerotic plaques development (29). Foam cells in vulnerable regions of atherosclerotic plaques produce MMP, which may mediate extracellular matrix degradation and consequent plaque destabilization.…”

Section: Discussionmentioning

confidence: 99%

A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients

Mesa

García-Rodríguez²,

Rico³

et al. 2017

Nutr Hosp

View full text Add to dashboard Cite

CM, Pérez-Rodríguez M, Pérez-de-laCruz AJ, Gil Á. A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for 6 weeks to elderly diabetic patients. AbstractBackground: Reducing the dietary glycaemic response has been proposed as a way to reduce the risk of diabetes complications. Objective: The aim of the present study was to evaluate the glycaemic control and cardiovascular risk biomarkers in fragile, elderly type 2 diabetes patients after the intake of a new fructose-free diabetes-specifi c formula enriched with resistant-starch type IV and high in monounsaturated fatty acids. Methods: Forty-one type 2 diabetes patients aged 78.9 ± 2.8 years were fed exclusively with an enteral diabetes-specifi c formula for 6 weeks. Data were collected at baseline and after 6 weeks of feeding. Carbohydrate and lipid metabolism and infl ammatory and cardiovascular risk biomarkers were measured to evaluated the course of diabetes complications. Results: Blood glycated haemoglobin signifi cantly decreased after the intervention (6.1 ± 0.1 vs. 5.8 ± 0.1 %; p < 0,045), as well as monocyte chemotactic protein-1 and soluble E-selectin (p < 0.05), while soluble vascular cell adhesion molecule and plasminogen activator inhibitor-1 tended to decrease from baseline to 6 weeks (p = 0.084 and p = 0.05, respectively). Conclusion:The new product improves glycaemic control and cardiovascular risk without altering lipid metabolism, which is useful for the prevention of diabetic complications. Longer intervention studies are needed in order to validate these results in a larger population.

show abstract

“…In appropriate settings, Lp(a), and its associated phosphocholine (PC)-containing oxidized phospholipids (OxPLs), also triggers apoptosis in macrophages, a key process that likely contributes to early valvular lesion progression (31). Furthermore, it was recently shown that Lp(a) binds monocyte chemoattractant protein-1 (MCP-1) in vitro and in vivo (32). The association of MCP-1 may play a role in modulating monocyte trafficking during early valve sclerosis.…”

Section: Future Directions: Can As Be Prevented By Lp(a) Targeted Thementioning

confidence: 99%

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

Thanassoulis

2016

Journal of Lipid Research

View full text Add to dashboard Cite

MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma

Cited by 78 publications

References 36 publications

Chemokines in Atherosclerosis

Chemokines in Atherosclerosis

A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

Contact Info

Product

Resources

About